The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform
Christopher J Weir - One of the best experts on this subject based on the ideXlab platform.
-
factors associated with outcome and Duration of therapy in outpatient parenteral antibiotic therapy opat patients with skin and soft tissue infections
International Journal of Antimicrobial Agents, 2011Co-Authors: R A Seaton, E Sharp, V Bezlyak, Christopher J WeirAbstract:This study was designed to identify factors associated with adverse outcomes and Increased Duration of parenteral therapy in patients with skin and soft-tissue infections (SSTIs) managed with outpatient parenteral antibiotic therapy (OPAT). A retrospective cohort study interrogating variables recorded prospectively in an electronic OPAT patient database was performed. 'OPAT failure' was defined as hospitalisation following initiation of OPAT, or adverse event or progression of infection necessitating a change in antibiotic therapy. Variables associated with failure or Increased Duration of therapy were identified via univariate and multiple logistic regression analyses. In total, 963 first patient episodes of OPAT-treated SSTIs were observed; 84% were treated with daily ceftriaxone and 15% with teicoplanin (three daily loading doses then three times per week). Progression of infection was observed in 2.8% of cases, inpatient management was required in 6% and significant adverse events occurred in 7.1%. Overall OPAT success was 87.1%. Female sex, diabetes and treatment with teicoplanin were independently associated with OPAT failure. A significant reduction in Duration of OPAT therapy was observed over time. A longer Duration of intravenous therapy was associated with meticillin-resistant Staphylococcus aureus (MRSA), older age, vascular disease, a diagnosis of bursitis, and treatment with teicoplanin. Non-inpatient referrals, management via a nurse-led patient group direction, and treatment with ceftriaxone were associated with reduced Duration of OPAT. For selected patients with SSTIs, OPAT was generally safe and effective, but specific patient groups were identified with more complex management pathways and poorer outcomes.
-
Factors associated with outcome and Duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections
International Journal of Antimicrobial Agents, 2011Co-Authors: R A Seaton, E Sharp, V Bezlyak, Christopher J WeirAbstract:This study was designed to identify factors associated with adverse outcomes and Increased Duration of parenteral therapy in patients with skin and soft-tissue infections (SSTIs) managed with outpatient parenteral antibiotic therapy (OPAT). A retrospective cohort study interrogating variables recorded prospectively in an electronic OPAT patient database was performed. 'OPAT failure' was defined as hospitalisation following initiation of OPAT, or adverse event or progression of infection necessitating a change in antibiotic therapy. Variables associated with failure or Increased Duration of therapy were identified via univariate and multiple logistic regression analyses. In total, 963 first patient episodes of OPAT-treated SSTIs were observed; 84% were treated with daily ceftriaxone and 15% with teicoplanin (three daily loading doses then three times per week). Progression of infection was observed in 2.8% of cases, inpatient management was required in 6% and significant adverse events occurred in 7.1%. Overall OPAT success was 87.1%. Female sex, diabetes and treatment with teicoplanin were independently associated with OPAT failure. A significant reduction in Duration of OPAT therapy was observed over time. A longer Duration of intravenous therapy was associated with meticillin-resistant (MRSA), older age, vascular disease, a diagnosis of bursitis, and treatment with teicoplanin. Non-inpatient referrals, management via a nurse-led patient group direction, and treatment with ceftriaxone were associated with reduced Duration of OPAT. For selected patients with SSTIs, OPAT was generally safe and effective, but specific patient groups were identified with more complex management pathways and poorer outcomes.
Ralph Lydic - One of the best experts on this subject based on the ideXlab platform.
-
perineural dexmedetomidine added to ropivacaine for sciatic nerve block in rats prolongs the Duration of analgesia by blocking the hyperpolarization activated cation current
Anesthesiology, 2011Co-Authors: Chad M Brummett, Elizabeth K Hong, Allison M Janda, Francesco S Amodeo, Ralph LydicAbstract:Background The present study was designed to test the hypothesis that the Increased Duration of analgesia caused by adding dexmedetomidine to local anesthetic results from blockade of the hyperpolarization-activated cation (Ih)current.
-
perineural dexmedetomidine provides an Increased Duration of analgesia to a thermal stimulus when compared with a systemic control in a rat sciatic nerve block
Regional Anesthesia and Pain Medicine, 2010Co-Authors: Chad M Brummett, Allison M Janda, Francesco S Amodeo, Amrita Padda, Ralph LydicAbstract:Background and Objectives: The present study was designed to test the hypothesis that perineural dexmedetomidine provides a longer Duration of analgesia than the same dose given subcutaneously in a peripheral nerve block in rats. Methods: Fifty-four rats received unilateral sciatic nerve blocks along with a subcutaneous injection at the base of the neck by a blinded investigator assigned at random. Combinations were as follows: perineural ropivacaine alone and subcutaneous (SQ) saline, perineural ropivacaine plus dexmedetomidine and SQ saline, perineural ropivacaine and SQ dexmedetomidine, perineural dexmedetomidine alone and SQ saline, and perineural saline and SQ dexmedetomidine. The ropivacaine concentration was fixed at 0.5%, and the dose of dexmedetomidine was 20.0 μg/kg (119.3 μmol/L). Sensory analgesia was assessed by paw withdrawal latency (PWL) to a thermal stimulus every 30 mins after the block for a minimum of 240 mins or until the return of normal sensory function. The unblocked paw served as the control for assessment of systemic, centrally mediated analgesia. Between-group and within-group comparisons of PWL were obtained for measures from operative and control paws. Results: The analgesic effect of perineural dexmedetomidine was superior to that of subcutaneous dexmedetomidine in ropivacaine sciatic nerve blocks from time points 120 to 210 mins (P Conclusions: Sensory analgesia provided by dexmedetomidine added to ropivacaine for peripheral nerve blocks in rat is a peripherally mediated effect.
R A Seaton - One of the best experts on this subject based on the ideXlab platform.
-
factors associated with outcome and Duration of therapy in outpatient parenteral antibiotic therapy opat patients with skin and soft tissue infections
International Journal of Antimicrobial Agents, 2011Co-Authors: R A Seaton, E Sharp, V Bezlyak, Christopher J WeirAbstract:This study was designed to identify factors associated with adverse outcomes and Increased Duration of parenteral therapy in patients with skin and soft-tissue infections (SSTIs) managed with outpatient parenteral antibiotic therapy (OPAT). A retrospective cohort study interrogating variables recorded prospectively in an electronic OPAT patient database was performed. 'OPAT failure' was defined as hospitalisation following initiation of OPAT, or adverse event or progression of infection necessitating a change in antibiotic therapy. Variables associated with failure or Increased Duration of therapy were identified via univariate and multiple logistic regression analyses. In total, 963 first patient episodes of OPAT-treated SSTIs were observed; 84% were treated with daily ceftriaxone and 15% with teicoplanin (three daily loading doses then three times per week). Progression of infection was observed in 2.8% of cases, inpatient management was required in 6% and significant adverse events occurred in 7.1%. Overall OPAT success was 87.1%. Female sex, diabetes and treatment with teicoplanin were independently associated with OPAT failure. A significant reduction in Duration of OPAT therapy was observed over time. A longer Duration of intravenous therapy was associated with meticillin-resistant Staphylococcus aureus (MRSA), older age, vascular disease, a diagnosis of bursitis, and treatment with teicoplanin. Non-inpatient referrals, management via a nurse-led patient group direction, and treatment with ceftriaxone were associated with reduced Duration of OPAT. For selected patients with SSTIs, OPAT was generally safe and effective, but specific patient groups were identified with more complex management pathways and poorer outcomes.
-
Factors associated with outcome and Duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections
International Journal of Antimicrobial Agents, 2011Co-Authors: R A Seaton, E Sharp, V Bezlyak, Christopher J WeirAbstract:This study was designed to identify factors associated with adverse outcomes and Increased Duration of parenteral therapy in patients with skin and soft-tissue infections (SSTIs) managed with outpatient parenteral antibiotic therapy (OPAT). A retrospective cohort study interrogating variables recorded prospectively in an electronic OPAT patient database was performed. 'OPAT failure' was defined as hospitalisation following initiation of OPAT, or adverse event or progression of infection necessitating a change in antibiotic therapy. Variables associated with failure or Increased Duration of therapy were identified via univariate and multiple logistic regression analyses. In total, 963 first patient episodes of OPAT-treated SSTIs were observed; 84% were treated with daily ceftriaxone and 15% with teicoplanin (three daily loading doses then three times per week). Progression of infection was observed in 2.8% of cases, inpatient management was required in 6% and significant adverse events occurred in 7.1%. Overall OPAT success was 87.1%. Female sex, diabetes and treatment with teicoplanin were independently associated with OPAT failure. A significant reduction in Duration of OPAT therapy was observed over time. A longer Duration of intravenous therapy was associated with meticillin-resistant (MRSA), older age, vascular disease, a diagnosis of bursitis, and treatment with teicoplanin. Non-inpatient referrals, management via a nurse-led patient group direction, and treatment with ceftriaxone were associated with reduced Duration of OPAT. For selected patients with SSTIs, OPAT was generally safe and effective, but specific patient groups were identified with more complex management pathways and poorer outcomes.
Chad M Brummett - One of the best experts on this subject based on the ideXlab platform.
-
perineural dexmedetomidine added to ropivacaine for sciatic nerve block in rats prolongs the Duration of analgesia by blocking the hyperpolarization activated cation current
Anesthesiology, 2011Co-Authors: Chad M Brummett, Elizabeth K Hong, Allison M Janda, Francesco S Amodeo, Ralph LydicAbstract:Background The present study was designed to test the hypothesis that the Increased Duration of analgesia caused by adding dexmedetomidine to local anesthetic results from blockade of the hyperpolarization-activated cation (Ih)current.
-
perineural dexmedetomidine provides an Increased Duration of analgesia to a thermal stimulus when compared with a systemic control in a rat sciatic nerve block
Regional Anesthesia and Pain Medicine, 2010Co-Authors: Chad M Brummett, Allison M Janda, Francesco S Amodeo, Amrita Padda, Ralph LydicAbstract:Background and Objectives: The present study was designed to test the hypothesis that perineural dexmedetomidine provides a longer Duration of analgesia than the same dose given subcutaneously in a peripheral nerve block in rats. Methods: Fifty-four rats received unilateral sciatic nerve blocks along with a subcutaneous injection at the base of the neck by a blinded investigator assigned at random. Combinations were as follows: perineural ropivacaine alone and subcutaneous (SQ) saline, perineural ropivacaine plus dexmedetomidine and SQ saline, perineural ropivacaine and SQ dexmedetomidine, perineural dexmedetomidine alone and SQ saline, and perineural saline and SQ dexmedetomidine. The ropivacaine concentration was fixed at 0.5%, and the dose of dexmedetomidine was 20.0 μg/kg (119.3 μmol/L). Sensory analgesia was assessed by paw withdrawal latency (PWL) to a thermal stimulus every 30 mins after the block for a minimum of 240 mins or until the return of normal sensory function. The unblocked paw served as the control for assessment of systemic, centrally mediated analgesia. Between-group and within-group comparisons of PWL were obtained for measures from operative and control paws. Results: The analgesic effect of perineural dexmedetomidine was superior to that of subcutaneous dexmedetomidine in ropivacaine sciatic nerve blocks from time points 120 to 210 mins (P Conclusions: Sensory analgesia provided by dexmedetomidine added to ropivacaine for peripheral nerve blocks in rat is a peripherally mediated effect.
V Bezlyak - One of the best experts on this subject based on the ideXlab platform.
-
factors associated with outcome and Duration of therapy in outpatient parenteral antibiotic therapy opat patients with skin and soft tissue infections
International Journal of Antimicrobial Agents, 2011Co-Authors: R A Seaton, E Sharp, V Bezlyak, Christopher J WeirAbstract:This study was designed to identify factors associated with adverse outcomes and Increased Duration of parenteral therapy in patients with skin and soft-tissue infections (SSTIs) managed with outpatient parenteral antibiotic therapy (OPAT). A retrospective cohort study interrogating variables recorded prospectively in an electronic OPAT patient database was performed. 'OPAT failure' was defined as hospitalisation following initiation of OPAT, or adverse event or progression of infection necessitating a change in antibiotic therapy. Variables associated with failure or Increased Duration of therapy were identified via univariate and multiple logistic regression analyses. In total, 963 first patient episodes of OPAT-treated SSTIs were observed; 84% were treated with daily ceftriaxone and 15% with teicoplanin (three daily loading doses then three times per week). Progression of infection was observed in 2.8% of cases, inpatient management was required in 6% and significant adverse events occurred in 7.1%. Overall OPAT success was 87.1%. Female sex, diabetes and treatment with teicoplanin were independently associated with OPAT failure. A significant reduction in Duration of OPAT therapy was observed over time. A longer Duration of intravenous therapy was associated with meticillin-resistant Staphylococcus aureus (MRSA), older age, vascular disease, a diagnosis of bursitis, and treatment with teicoplanin. Non-inpatient referrals, management via a nurse-led patient group direction, and treatment with ceftriaxone were associated with reduced Duration of OPAT. For selected patients with SSTIs, OPAT was generally safe and effective, but specific patient groups were identified with more complex management pathways and poorer outcomes.
-
Factors associated with outcome and Duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections
International Journal of Antimicrobial Agents, 2011Co-Authors: R A Seaton, E Sharp, V Bezlyak, Christopher J WeirAbstract:This study was designed to identify factors associated with adverse outcomes and Increased Duration of parenteral therapy in patients with skin and soft-tissue infections (SSTIs) managed with outpatient parenteral antibiotic therapy (OPAT). A retrospective cohort study interrogating variables recorded prospectively in an electronic OPAT patient database was performed. 'OPAT failure' was defined as hospitalisation following initiation of OPAT, or adverse event or progression of infection necessitating a change in antibiotic therapy. Variables associated with failure or Increased Duration of therapy were identified via univariate and multiple logistic regression analyses. In total, 963 first patient episodes of OPAT-treated SSTIs were observed; 84% were treated with daily ceftriaxone and 15% with teicoplanin (three daily loading doses then three times per week). Progression of infection was observed in 2.8% of cases, inpatient management was required in 6% and significant adverse events occurred in 7.1%. Overall OPAT success was 87.1%. Female sex, diabetes and treatment with teicoplanin were independently associated with OPAT failure. A significant reduction in Duration of OPAT therapy was observed over time. A longer Duration of intravenous therapy was associated with meticillin-resistant (MRSA), older age, vascular disease, a diagnosis of bursitis, and treatment with teicoplanin. Non-inpatient referrals, management via a nurse-led patient group direction, and treatment with ceftriaxone were associated with reduced Duration of OPAT. For selected patients with SSTIs, OPAT was generally safe and effective, but specific patient groups were identified with more complex management pathways and poorer outcomes.
